Key information

🔎 Fund Overview

TuHURA Biosciences, Inc. is a Phase III registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The Company’s personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase III registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first line treatment for advanced Merkel cell carcinoma. It is leveraging its Delta receptor technology to develop tumor microenvironment modulators in the form of first-in-class bi-specific antibody-peptide conjugates (APCs) and antibody-drug conjugates (ADCs) targeting Myeloid Derived Suppressor Cells (MDSCs). In addition to its innate immune agonist candidates, the Company plans to advance its VISTA-inhibiting antibody into a phase II trial in combination with a menin inhibitor in NPM1 mutated relapsed or refractory AML.